Pegylated interferon for the treatment of high risk essential thrombocythemia: Results of a phase II study

Haematologica

Volumn 90, Issue 10, 2005, Pages 1333-1338

  Langer, Christian ^a   Lengfelder, Eva ^b   Thiele, Jürgen ^c   Kvasnicka, Hans M ^c   Pahl, Heike L ^d   Beneke, Heimo ^a   Schauer, Stefanie ^a   Gisslinger, Heinz ^e   Griesshammer, Martin ^a,f  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Department of Medicine III ^*  (Germany)

Author keywords

Essential thrombocythemia; ET; Pegylated interferon; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; PEGINTERFERON; PEGINTERFERON ALPHA2B;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRY SKIN; FATIGUE; FLU LIKE SYNDROME; HAIR LOSS; HEADACHE; HIGH RISK POPULATION; HUMAN; MICROANGIOPATHY; MYALGIA; MYELOFIBROSIS; PATIENT; PHASE 2 CLINICAL TRIAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; WORLD HEALTH ORGANIZATION;

ADULT; AGED; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PLATELET COUNT; POLYETHYLENE GLYCOLS; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 27144539129     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Johansson P, Kutti J, Andreasson B, Safai-Kutti S, Vilen L, Wedel H, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Intern Med 2004; 256:161-5.
2. Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13:150-4.
3. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 2005; 353:85-6.
4. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8:556-62.
5. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89:215-32.
6. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev 2001;15:121-31.
7. Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R, et al. Chronic myeloproliferative disorders. Hematology (Am Soc Hematol Educ Program) 2003; 200-24.
8. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-36.
9. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
10. Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996;52:42-6.
11. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91:616-22.
12. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-83.
13. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera. An analysis of 1,638 patients enrolled in a prospective observational study. Blood 2005;105:2664-70.
14. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996; 22 Suppl 1:135-42.
15. Bentley M, Taylor K, Grigg A, Kronenberg H, Gibson J, Bunce I, et al. Long-term interferon-α 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leuk Lymphoma 1999;36: 123-8.
16. Saba R, Jabbour E, Giles F, Cortes J, Talpaz M, O'brien S, et al. Interferon α therapy for patients with essential thrombocythemia. Cancer 2005; 103: 2551-7.
17. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-α-2b formulation. Cancer 2002;95:389-96.
18. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, et al. Pilot study of pegylated interferon-α 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 2003;51:81-6.
19. Samuelsson J, Hasselbakh H, Bruserud O, Pahl H, Merup M, Linder O, et al. A Phase II Trial of Pegylated Interferon α-2b in polycythemia vera and essential thrombocythemia. Clinical responses, effects on PRV-1 expression and impact on quality of life. Blood 2004;ASH abstract 1518[Abstract].
20. Gugliotta L, Bulgarelli S, Tieghi A, Asioli S, Gardini G, Vianelli N, et al. Bone marrow biopsy and aspirate evaluation in 90 patients with essential thrombocythemia treated with PEG interferon α-2b. Preliminary results. Blood 2004; ASH 1523 [abstract].
21. Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H, et al. PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol 2004; 83:364-70.
22. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003;102: 3569-74.